Early Access Programs (EAPs) in France provide pharmaceutical and biotech companies with a valuable opportunity to offer patients innovative treatments before obtaining formal marketing authorization. Regulated by the French National Agency for the Safety of [...]
In my previous article, "One Size Doesn’t Fit All: Why CRO Flexibility Matters More Than Ever" I discuss how each clinical trial and each Sponsor has unique needs, meaning there can be no one-size-fits all [...]
The 5th Annual Operationalize Expanded Access Programs (EAP) Conference, held in Boston this March, once again brought together industry leaders and key stakeholders to discuss the evolving landscape of expanded access and post-trial access programs. [...]
Expanded Access Programs (EAPs) allow patients with serious or life-threatening conditions to obtain investigational treatments outside of the clinical trial setting. Because they are not formal clinical trials, EAPs do not require as much data [...]
WEP Clinical (WEP), a clinical services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when treatment options are limited or unavailable, has partnered with Plusultra pharma (PUP) [...]
